Rocket One RKTO
NASDAQ RKTO
$0.35 -0.03 (-7.92%)
As of: Nov 11, 2026 · 9:56 AM EST

Rocket One (RKTO) Other Non-Current Assets (2018 - 2026)

Updated

Rocket One's Other Assets was $967,135 in Q2 2026, up 27.8% from the prior quarter.

Analysis

Rocket One (RKTO) Other Non-Current Assets (2018 - 2026) Analysis & Trends

At the end of FY2025, Other Assets at Rocket One came in at $756,591.

  • Other Assets shows a five-year compound annual growth rate of -22.1% (FY2020 to FY2025).
  • In earlier years, Other Assets was $92,565 in FY2023.
  • The Q2 2026 figure marks the highest quarterly Other Assets since Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 7.70 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 15.10 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.42 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 19.90 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - 700.00 Mn
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 14.60 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 4.90 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.02 Bn
10 Rocket One 8.81 Mn -17.22 Mn - 967,135.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 967,135.00
Mar 31, 2026 756,591.00
Dec 31, 2025 756,591.00
Sep 30, 2025 333,150.00
Jun 30, 2025 402,747.00
Dec 31, 2024 476,235.00
Mar 31, 2024 635,541.00
Dec 31, 2023 92,565.00
Dec 31, 2020 2.63 Mn
Jun 30, 2020 4.95 Mn
Mar 31, 2020 4.55 Mn
Dec 31, 2019 1.92 Mn
Sep 30, 2019 3.41 Mn
Jun 30, 2019 4.09 Mn
Mar 31, 2019 5.17 Mn
Dec 31, 2018 206,671.00
API Access

Rocket One Other Non-Current Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-assets&ticker=RKTO&period=max&api_key=YOUR_API_KEY